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Abstract
Background
Patients with testicular germ cell tumors (TGCT) have an increased risk for venous thrombo-
embolism (VTE). We identified risk factors for VTE in this patient cohort and developed a
clinical risk model.
Methods
In this retrospective cohort study at the Medical University of Graz we included 657 conse-
cutive TGCT patients across all clinical stages. A predictive model for VTE was developed
and externally validated in 349 TGCT patients treated at the University Hospital Zurich.
Results
Venous thromboembolic events occurred in 34 (5.2%) patients in the Graz cohort. In univari-
able competing risk analysis, higher clinical stage (cS) and a retroperitoneal lymphadenopa-
thy (RPLN) were the strongest predictors of VTE (p<0.0001). As the presence of a RPLN
with more than 5cm in greatest dimension without coexisting visceral metastases is classified
as cS IIC, we constructed an empirical VTE risk model with the following four categories (12-
month-cumulative incidence): cS IA-B 8/463 patients (1.7%), cS IS-IIB 5/86 patients (5.9%),
cS IIC 3/21 patients (14.3%) and cS IIIA-C 15/70 patients (21.4%). This risk model was exter-
nally validated in the Zurich cohort (12-month-cumulative incidence): cS IA-B (0.5%), cS IS-
IIB (6.0%), cS IIC (11.1%) and cS IIIA-C (19.1%). Our model had a significantly higher dis-
criminatory performance than a previously published classifier (RPLN-VTE-risk-classifier)
which is based on the size of RPLN alone (AUC-ROC: 0.75 vs. 0.63, p = 0.007).
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Conclusions
According to our risk stratification, TGCT patients with cS IIC and cS III disease have a very
high risk of VTE and may benefit from primary thromboprophylaxis for the duration of
chemotherapy.
Introduction
Testicular germ cell tumors (TGCT) represent one of the most curable solid malignancies as
cisplatin-based chemotherapy is highly efficacious in achieving durable remissions even in
widely metastatic disease [1–3]. The recent focus of clinical research in TGCT has therefore
shifted on the prevention of treatment-related complications like venous thromboembolism
(VTE) [4]. The risk of VTE is increased around 4–6 fold in cancer patients as compared to the
general population [5,6]. Moore et al. have demonstrated a very high incidence of thromboem-
bolic events in patients receiving cisplatin-based chemotherapy [7]. Thromboembolic events
have a high impact on morbidity of cancer patients and are negative predictors of survival [8–
12]. Therefore predictive factors for VTE are needed to identify subgroups with the highest
risk and thus the potentially greatest benefit from primary thromboprophylaxis. Khorana et al.
recently developed a predictive model for chemotherapy-associated VTE [6]. However, the
validation of the Khorana model included only 39 patients with TGCT [13]. Recently, Sri-
kanthan et al. have shown that a large (more than 5cm in maximal axial diameter) retroperito-
neal lymphadenopathy (RPLN) is a strong risk factor for VTE in TGCT, and that this
predictor provides a higher discriminatory accuracy for the prediction of VTE than the Khor-
ana score. However, the study by Srikanthan included only patients with disseminated TGCT
[13]. In this study, we examined the incidence of VTE in TGCT patients across all clinical
stages and developed a clinical risk model for VTE in patients with TGCT.
Materials and methods
Subjects
All consecutive patients (n = 657) with histologically confirmed TGCT, presenting to the Divi-
sion of Oncology at the Medical University of Graz between January 2000 and December
2013, were retrospectively reviewed. Patients were initially staged using computed tomo-
graphic (CT) scans of the abdomen, CT scan or X-ray of the chest and postoperative tumor
markers α-fetoprotein (AFP), human chorionic gonadotropin (HCG) and lactate dehydroge-
nase (LDH). Patients with disseminated disease were risk-classified according to the Interna-
tional Germ Cell Cancer Collaborative Group (IGCCCG) classification [14,15].
Follow-up data were retrieved until January 2015. Follow-up investigations at our center
were performed according to a local protocol and were adapted in 2007 and 2012 according to
recent publications [16–18]. Electronic and paper medical records of all 657 consecutive TGCT
patients were retrospectively reviewed and thromboembolic events were documented in our in-
house administrative system. VTE was defined as symptomatic or incidental deep vein throm-
bosis (DVT), visceral thrombosis and pulmonary embolism (PE) and had to be confirmed by
imaging such as angiography, venous doppler ultrasound, magnetic resonance imaging, com-
puted tomography or ventilation/perfusion scan. Patients with VTE at cancer diagnosis (n = 3)
were not counted as VTE events. All VTE events during the first year of follow-up were consid-
ered for the development of the VTE risk stratification rule. The validation cohort consisted of
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349 consecutive TGCT patients treated at the University Hospital Zurich between January 2003
until December 2013. Patient records were anonymized and de-identified prior to analysis. The
study was approved by the Institutional Review Board of the Medical University of Graz (No.
26–196 ex 13/1) and the Kantonale Ethikkomission Zurich (KEK StV-No.25-2008).
Statistical analysis
All statistical analyses were performed using Stata (Windows version 13.0, Stata Corp., Hous-
ton, TX, USA). Fatal and non-fatal, symptomatic or incidental VTE was defined as the primary
endpoint of this analysis. In both the development and the external validation cohort, the risk
of VTE was estimated with competing risk cumulative incidence estimators according to Maru-
bini & Valsecchi.(Stata routine stcompet) [19]. Cumulative incidence functions between two or
more groups were compared with Gray’s test (self-written routine stgrays) [20]. Uni- and mul-
tivariable modeling of time-to-VTE was performed with Fine & Gray proportional subdistribu-
tion hazards models (Stata routine stcrreg) [21]. All these competing risk analyses considered
mortality as the competing event of interest. Risk of mortality was analyzed using the inverse of
the Kaplan-Meier product limit estimator, the log-rank test, and the Cox model. We evaluated
the impact of VTE on mortality with a clock-forward, Semi-Markov, three-state, unidirectional
illness-death model with proportional hazards for the transitions into the death state [22].
Next, we aimed to derive an empirical risk stratification rule for thrombotic risk in all
TGCT patients. This rule was first developed in the Graz cohort, and then externally validated
in the Zurich cohort. Model development in the Graz cohort was performed by considering
the variables with the strongest association with VTE in univariable competing risk analysis
combined with a subject-matter-knowledge-approach [22]. In detail, stage and chemotherapy
were highly collinear. Given that stage emerged as a stronger VTE predictor than chemother-
apy (as indicated by χ2 statistics) and showed also the highest discriminatory potential towards
VTE (as indicated by Harrell’s C statistic), we decided to keep stage as a fixed variable in the
model building process [23]. RPLN was included as a second variable in the risk stratification
model because in a subgroup analysis of patients with metastasized cS IS–IIIC disease, the
most relevant predictors of VTE were clinical stage III disease and a large RPLN. As the pres-
ence of a RPLN with more than 5cm in greatest dimension without coexisting visceral metasta-
ses is classified as stage IIC, we further subdivided our tumor stage variable and hence
constructed the empirical VTE risk stratification rule with the following four categories cS
IA-B, cS IS-IIB, cS IIC and cS IIIA-C. In external validation, we pre-specified to consider the
model successfully validated given it achieves a comparable C-Index for discrimination and
comparable absolute VTE risks in the risk groups defined by the risk model [23].
The areas under the receiver-operating-characteristic-curve (AUC-ROC) for the
RPLN-VTE-risk-classifier according to Srikanthan et al. and the novel risk model were com-
pared non-parametrically using a chi-squared test (Stata routine rocgold) [13,24]. In a clinical
benefit/risk analysis the number-needed-to-treat in VTE risk subgroups was calculated as the
inverse of the absolute risk reduction, assuming a 50% reduction in the relative risk of VTE
with primary prophylaxis. Conversely, we assumed a 25% relative increase in the risk of major
and clinically relevant non-major bleeding to calculate the number-needed-to-harm as the
inverse of the absolute increase with primary prophylaxis of VTE [25].
Results
Patient characteristics
Six-hundred-fifty-seven TGCT patients were identified at the Medical University of Graz
(‘Graz Cohort’) and 349 TGCT patients at the University Hospital Zurich for the validation
Testicular cancer and thromboembolism
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cohort (‘Zurich cohort’). The cohorts were well matched and proportions of the IGCCCG risk
groups were consistent with the literature (Table 1) [14,26]. All patients with metastatic disease
received cisplatin based chemotherapy. Baseline characteristics of the Graz cohort are listed in
Table 2. In the Graz cohort 22 out of 657 (3.3%) and in the Zurich cohort 7 out of 349 (2.0%)
patients received primary thromboprophylaxis with low molecular weight heparin for the
duration of their chemotherapy. Prophylaxis was prescribed at the individual physician’s dis-
cretion. Vitamin K antagonists and new oral anticoagulants were not used. Of those prescribed
thromboprophylaxis, 2 out of 22 patients in the Graz cohort and 3 out of 7 patients in the
Zurich cohort suffered from VTE. To rule out bias by not excluding these small numbers of
patients with thromboprophylaxis a sensitivity analysis was performed. Sensitivity analyses
showed that some measures tended to be even stronger after exclusion of patients with primary
thromboprophylaxis (Harell’s C coefficient including all patients in the Graz cohort was 0.75,
and 0.76 after excluding these patients. The univariable hazard ratio for large retroperitoneal
lymphadenopathy in the Graz cohort was 6.8 including all patients, and 8.3 excluding the 22
patients).
Cumulative risk of VTE in the Graz cohort
Over a median follow-up of 6.6 years (range: 21 days– 14.7 years), 34 VTE events (5.2%)
occurred in 657 patients. The cumulative 3-month, 6-month, 12-month, 24-month, and 5-year
incidence of VTE accounting for death as a competing risk was 3.7% (95%CI: 2.4–5.3), 4.1%
(95%CI: 2.8–5.8), 4.8% (95%CI: 3.3–6.6), 4.9% (95%CI: 3.4–6.8), and 5.3% (95%CI: 3.7–7.2).
The most frequent type of VTE event was PE, followed by DVT (Table 3).
Impact of VTE on mortality in the Graz cohort
The cumulative risk of mortality in the overall study population was 3.6% (95%CI: 2.3–5.6).
This risk varied according to clinical stage, with an overall 5-year mortality of 1.0% (0.4–2.7),
Table 1. Patient clinical characteristics.
University of Graz University of Zurich
N = 657 N = 349
Number (%missing) Percentage Number (%missing) Percentage
Median Age, years 35.9 34.9
Histology (1.4%) (0.6%)
Seminoma 388 59.9 197 56.8
Nonseminoma 260 40.1 150 43.2
Clinical tumor stage (2.6%) (0.0%)
Stage IA-B 463 72.3 226 64.8
Stage IS 9 1.4 9 2.6
Stage IIA-IIC 98 15.3 50 14.3
Stage IIIA-C 70 10.9 64 18.3
IGCCCG risk group (0.0%) (7.3%)
Good 137 76.1 77 67.6
Intermediate 19 10.6 21 18.4
Poor 24 13.3 16 14.0
VTE events 34 5.2 18 5.2
Primary Thromboprophylaxis 22 3.3 7 2.0
IGCCCG, International Germ Cell Cancer Collaborative Group; VTE, venous thromboembolism.
https://doi.org/10.1371/journal.pone.0176283.t001
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Table 2. Baseline characteristics of the Graz cohort—Distribution overall and by VTE status.
Variable Subjects with available
data {%missing}
Overall Graz
cohort (n = 657)
VTE during
follow-up (n = 34)
No VTE during
follow-up (n = 623)
P*
Demographic
characteristics
Age, years 657 {0.0%} 35.9 [29.2–43.0] 36.5 [27.7–40.1] 35.7 [29.2–43.1] 0.5
BMI, kg/m 634 {3.5%} 24.7 [22.8–27.2] 23.9 [21.8–26.3] 24.8 [22.9–27.4] 0.11
Family history of TGCT** 463 {29.5%} 17 (3.7%) 0 (0.0%) 17 (3.8%) 0.39
Smoker or Ex-Smoker 555 {15.5%} 281 (50.6%) 11 (50.0%) 270 (50.7%) 0.95
Karnofsky Index <100% 647 {1.5%} 66 (10.2%) 10 (30.3%) 56 (9.1%) <0.0001
Clinicopathological
variables
Non-Seminomatous
histology
648 {1.4%} 260 (40.1%) 22 (66.7%) 238 (38.7%) 0.001
Clinical tumor stage 640 {2.6%} <0.0001
stage IA-IB 463 (72.3%) 10 (2.2%) 453 (97.8%)
stage IS 9 (1.4%) 1 (11.1%) 8 (88.9%)
stage IIA–IIC 98 (15.3%) 8 (8.2%) 90 (91.8%)
stage IIIA–IIIC 70 (10.9%) 15 (21.4%) 55 (78.6%)
RPLN(>5cm) 652 {0.8%} 50 (7.7%) 11 (22.0%) 39 (78.0%) <0.0001
IGCCCG risk stratification 180 {0.0%} 0.004
Good risk 137 (76.1%) 13 (9.5%) 124 (90.5%)
Intermediate risk 19 (10.6%) 7 (36.8%) 12 (63.2%)
Poor risk 24 (13.3%) 4 (16.7%) 20 (83.3)
Chemotherapy cycles 653 {0.6%} <0.0001
0 cycles 367 (56.2%) 4 (1.1%) 363 (98.9%)
1 cycle 37 (5.7%) 0 (0.0%) 37 (100%)
2 cycles 91 (13.9%) 6 (6.6%) 85 (93.4%)
3 cycles 105 (16.1%) 10 (9.5%) 95 (90.5%)
4 cycles 53 (8.1%) 14 (26.4%) 39 (73.6%)
Laboratory parameters
Hemoglobin, g/dL (13-
17.5)
464 15.4 [14.7 1–16.2] 15.6 [14.6–16.1] 15.4 [14.7–16.2] 0.93
WBC, G/L (4.4–11.3) 461 7.7 [6.2–9.5] 8.2 [6.0–9.3] 7.7 [6.2–9.5] 0.93
Platelet count, G/L (140–
440)
461 231 [199–273] 226 [191–274] 232 [201–273] 0.59
CRP, mg/L ( 5) 427 1.8 [1.0–7.7] 6.7 [2.4–51.0] 1.8 [1.0–6.3] 0.004
Fibrinogen, mg/dL (210 –
400)
405 313 [250–425] 410 [324–653] 309 [249–418] 0.003
Tumor markers
Preoperative AFP, ng/
mL ( 15)
581 5.2 [3.0–12.0] 14.0 [3.3–517.7] 5.0 [3.0–10.1] 0.008
Preoperative betaHCG,
mU/mL ( 5)
592 5.0 [2.0–11.2] 6.1 [2.0–48.5] 5.0 [2.0–9.4] 0.12
Preoperative LDH, U/L
(120-240)
474 216 [178–295] 343 [237–800] 212 [175–283] <0.0001
Khorana Score 586 0.002
Score = 1 502 (85.7%) 20 (4.0%) 482 (96.0%)
Score = 2 75 (12.8%) 10 (13.3%) 65 (86.7%)
Score = 3 9 (1.5%) 0 (0.0%) 9 (100%)
Follow-up data
Recurrence of cancer 657 {0.0%} 63 (9.6%) 10 (29.4%) 53 (8.5%) < 0.0001
(Continued )
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3.0% (1.0–8.9), and 16.7% (9.6–28.2) in cS I, cS II and cS III disease, respectively (p<0.0001).
In a unidirectional multi-state model, the onset of VTE was associated with a 4-fold increase
in the risk of death (transition hazard ratio (THR) = 4.0, 95%CI: 1.2–13.8, p = 0.03). However,
this association did not persist after adjusting for tumor stage (adjusted THR for VTE = 1.2,
95%CI: 0.3–4.2, p = 0.82), suggesting that the adverse univariable association between VTE
and an unfavourable survival experience is confounded by the strong association between
higher tumor stage and higher mortality. In a landmark analysis, patients that experienced
VTE within the landmark date 3 months after baseline had a significantly worse 5 year survival
than patients who did not develop VTE (92.6% vs 97.7%, Mantel-Byar p = 0.01).
Predictors of VTE in the Graz cohort
Because VTEs almost exclusively occurred during the first year of follow-up, we restricted the
following time-to-event analyses to a 1-year time interval. In univariable competing risk analy-
sis, performance status, higher tumor stage, chemotherapy, non-seminomatous histology,
large RPLN, higher IGCCCG risk classification, elevated tumor markers, CRP, fibrinogen and
elevated Khorana score (i.e. > the 1 point assigned for testicular cancer) were significantly
associated with an increased one-year risk of VTE (Table 4). The two strongest predictors for
an increased risk of VTE were stage (χ2 on 2 degrees of freedom = 36.5). and chemotherapy
(χ2 on 1 degree of freedom = 16.7). Therefore, multivariable adjustment for these variables was
performed (Table 4). Due to the strong collinearity between stage and chemotherapy leading
Table 2. (Continued)
Variable Subjects with available
data {%missing}
Overall Graz
cohort (n = 657)
VTE during
follow-up (n = 34)
No VTE during
follow-up (n = 623)
P*
Death 655 {0.3%} 19 (2.9%) 3 (8.8%) 16 (2.6%) < 0.04
Median follow up 657 {0.0%} 6.6 [9.7–3.3]
Continuous data are reported as medians with 25th percentile– 75th percentile in the squared brackets, categorical data are reported as absolute
frequencies and percentages in parentheses. Percentages are calculated by referring only to the patients without missing values (i.e. not to the total number
of patients if missing values are present). VTE, venous thromboembolism; BMI, Body Mass Index; TGCT, testicular germ cell tumor; RPLN, retroperitoneal
lymphadenopathy; IGCCCG, International Germ Cell Cancer Collaborative Group; WBC, white blood count; CRP, C-reactive protein; AFP, alpha
Fetoprotein; betaHCG, beta Human Choriogonadotropin; LDH, Lactate dehydrogenase.
*p represents test for difference between VTE and No VTE (χ2 tests for binary and categorical variables, ranksum-tests for continuous variables),
**Family history is defined as a history of testicular cancer in a first and/or second degree relative;
https://doi.org/10.1371/journal.pone.0176283.t002
Table 3. Overall incidence of Venous thromboembolic events (Graz cohort).
Type of thromboembolic event No. of Patients (N = 657)
All 34 (5.2%)
DVT alone 8 (23.5%)
PE alone 20 (58.8%)
DVT and PE 5 (14.7%)
Visceral TE 1 (2.9%)
Symptomatic 22 (64.7%)
Incidental 12 (35.3%)
Fatal 1 (2.9%)
TE, thromboembolism; DVT, deep venous thrombosis; PE, pulmonary embolism.
https://doi.org/10.1371/journal.pone.0176283.t003
Testicular cancer and thromboembolism
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to model instability upon inclusion of both of these variables, this adjustment was done sepa-
rately. For subsequent multivariable analyses, we only considered stage because this variable
showed a stronger association with (see χ2 above) and a slightly higher discriminatory poten-
tial (ROC-AUC = 0.77 vs. ROC-AUC = 0.76) towards VTE than chemotherapy, respectively.
In a subgroup analysis of only patients with metastasized cS IS–IIIC disease (n = 177, i. e. a
population that corresponds to the development cohort of the Srikanthan model), the most
relevant predictors of VTE were clinical stage III disease, a large RPLN and intermediate/poor
IGCCCG risk (Table 5). In a subgroup analysis of only stage IIIA-C patients (n = 70), a large
Table 4. Baseline parameters and one-year risk of VTE in TGCT patients (Graz cohort)—Uni—And multivariable competing risk regression (Fine &
Gray proportional hazards model).
Univariable analysis Multivariable analysis
adjusted for tumor stage
Multivariable analysis adjusted
for chemotherapy
Variable SHR 95%CI p SHR 95%CI P SHR 95%CI p
Demographic characteristics
Age (per 5 year increase) 0.88 0.74–1.05 0.15 0.91 0.77–1.07 0.27 0.97 0.83–1.14 0.73
BMI (per 5kg/m2 increase) 0.70 0.40–1.22 0.21 0.81 0.51–1.29 0.37 0.74 0.45–1.24 0.26
Family history N/A N/A N/A
Smoker or Ex-Smoker 0.97 0.40–2.33 0.95 0.86 0.35–2.12 0.76 0.79 0.33–1.90 0.60
Karnofsky Index <100% 4.65 2.18–9.93 <0.0001 2.24 0.97–5.24 0.06 3.45 1.59–7.51 0.002
Clinical variables
Non-Seminomatous histology 4.23 1.88–9.49 <0.0001 2.29 0.84–6.25 0.11 1.61 0.67–3.88 0.29
Clinical tumor stage
- - -stage IA-IB (reference category)
- - -stage IS, IIA-IIC 4.47 1.68–11.9 0.003 N/A 1.97 0.73–5.32 0.18
- - -stage IIIA-IIIC 13.82 5.88–32.50 <0.0001 N/A 4.87 1.97–12.00 0.001
RPLN (>5cm) 7.81 3.71–16.43 <0.0001 2.11 0.86–5.16 0.10 3.29 1.54–7.05 0.002
IGCCCG risk stratification
- - -Good risk (reference category)
- - -Not good risk (Intermediate and poor risk) 3.19 1.42–7.21 0.005 N/A 2.61 1.16–5.88 0.02
Chemotherapy 19.59 4.71–81.58 <0.0001 9.27 2.07–41.44 0.004 N/A
Laboratory variables
Preoperative
- - -Hemoglobin (per 1g/dL increase) 0.92 0.70–1.21 0.54 1.09 0.87–1.35 0.46 0.95 0.74–1.22 0.68
- - -WBC (per 1G/L increase) 1.04 0.88–1.23 0.62 1.01 0.87–1.18 0.88 0.99 0.83–1.19 0.91
- - -Platelet count (per 50G/L increase) 1.06 0.70–1.61 0.78 0.90 0.69–1.17 0.43 0.93 0.63–1.36 0.70
- - -CRP (per 1log increase) 1.47 1.15–1.88 0.002 1.04 0.79–1.36 0.81 1.26 0.98–1.63 0.07
- - -Fibrinogen (per 100mg/dL increase) 1.36 1.13–1.64 0.001 1.00 0.81–1.25 0.97 1.18 0.96–1.45 0.11
Tumor markers (preoperative)
- - -AFP (per 1log increase) 1.36 1.20–1.54 <0.0001 1.18 1.00–1.38 0.05 1.22 1.07–1.39 0.003
betaHCG (per 1log increase) 1.21 1.07–1.37 0.003 1.05 0.91–1.20 0.52 1.09 0.95–1.26 0.21
LDH (per 1log increase) 3.27 2.11–5.08 <0.0001 1.86 1.06–3.25 0.03 2.37 1.48–3.80 <0.0001
Khorana Score
Score = 1 (reference category)
Score2 3.72 1.70–8.13 0.001 1.91 0.84–4.32 0.12 2.22 1.02–4.85 0.05
VTE, venous thromboembolism; TGCT, testicular germ cell tumor; SHR, subhazard ratio; CI, confidence interval; BMI, Body Mass Index; RPLN,
retroperitoneal lymphadenopathy; IGCCCG, International Germ Cell Cancer Collaborative Group; WBC, white blood count; CRP, C-reactive protein; AFP,
alpha Fetoprotein; ß-HCG, beta Human Choriogonadotropin; LDH, Lactate dehydrogenase.
https://doi.org/10.1371/journal.pone.0176283.t004
Testicular cancer and thromboembolism
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RPLN did not emerge as a significant predictor of VTE risk (SHR = 1.84, 95%CI: 0.65–5.23,
p = 0.25) suggesting that other contributing factors (greater burden of disease) increase the
risk of VTE.
In a subgroup analysis of patients with non-metastasized cS IA-B disease, we found that
adjuvant chemotherapy was associated with a 4-fold increase in the risk of VTE when com-
pared to those cS IA-B patients without adjuvant chemotherapy (Hazard Ratio = 4.0, 95%CI:
1.1–13.9, p = 0.03) (Table 5).
Table 5. Subgroup analysis: Baseline parameters and the one-year risk of VTE in TGCT patients with non-metastasized disease and metastasized
disease—–Fine & Gray competing risk regression.
Univariable analysis in cS IA-IB (463
patients)
Univariable analysis in cS IS-IIIC (177 patients)
Variable SHR 95%CI P SHR 95%CI P
Demographic characteristics
Age (per 5 year increase) 1.14 0.89–1.44 0.29 0.83 0.68–1.00 0.05
BMI (per 5kg/m2 increase) 1.19 0.54–2.63 0.67 0.66 0.37–1.18 0.16
Family history N/A N/A
Smoker or Ex-Smoker 1.02 0.21–5.04 0.98 0.91 0.32–2.58 0.86
Karnofsky Index < 100% 2.23 0.28–17.42 0.45 2.61 1.12–6.09 0.03
Clinicopathological variables
Non-Seminomatous histology 14.92 1.85–120.42 0.01 1.57 0.64–3.86 0.32
Clinical tumor stage
- - -stage IA—IB (reference category) N/A N/A
- - -stage IS, IIA—IIC N/A stage IS—IIC (reference category)
- - -stage IIIA—IIIC N/A 3.08 1.31–7.27 0.01
RPLN (>5cm) N/A 2.71 1.18–6.24 0.02
IGCCCG risk stratification
- - -Good risk (reference category)
- - -Not good risk (Intermediate and poor risk) N/A 3.12 1.38–7.04 0.006
Chemotherapy 7.84 1.60–38.50 0.01 4.20x1032* N/A N/A
Radiotherapy N/A 6.76x10-20* N/A N/A
Laboratory parameters
Preoperative
- - -Hemoglobin (per 1g/dL increase) 1.17 0.67–2.06 0.57 1.05 0.76–1.45 0.77
- - -WBC (per 1G/L increase) 0.96 0.79–1.17 0.69 1.06 0.85–1.32 0.62
- - -Platelet count (per 50G/L increase) 0.91 0.61–1.38 0.67 0.93 0.63–1.37 0.71
- - -CRP (per 1log increase) 1.03 0.80–1.33 0.81 1.15 0.84–1.57 0.39
- - -Fibrinogen (per 100mg/dL increase) 0.92 0.63–1.35 0.67 1.13 0.89–1.44 0.33
Preoperative AFP (per 1log increase) 1.45 1.13–1.86 0.004 1.17 1.00–1.36 0.05
Preoperative betaHCG (per 1log increase) 1.07 0.61–1.89 0.80 1.10 0.96–1.26 0.19
Preoperative LDH (per 1log increase) 2.89 0.99–8.44 0.05 2.03 1.17–3.53 0.01
Khorana Score
Score = 1 (reference category)
Score2 N/A 2.66 1.08–6.53 0.03
VTE, venous thromboembolism; TGCT, testicular germ cell tumor; BMI, Body Mass Index; RPLN, retroperitoneal lymphadenopathy; IGCCCG, International
Germ Cell Cancer Collaborative Group; LDH, Lactate dehydrogenase; WBC, white blood count; CRP, C-reactive protein; AFP, alpha Fetoprotein; ß-HCG,
beta Human Choriogonadotropin;
*these HR are extremely high or extremely small, which is indicative of model instability; this is because VTE events were almost exclusively clustered in
patients who received chemotherapy, whereas the very few patients that received radiotherapy were stage II seminomas.
https://doi.org/10.1371/journal.pone.0176283.t005
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A stratification for 12-month risk of TGCT-associated VTE
In our model, higher tumor stage and a large RPLN where the main risk factors for VTE in
patients with metastasized disease. As the presence of a RPLN with more than 5cm in greatest
dimension without coexisting visceral metastases is classified as stage IIC, we constructed an
empirical VTE risk stratification rule with the following four categories: cS IA-B (12-month
VTE risk: 1.7%), cS IS-IIB (5.9%), cS IIC (14.3%), and cS IIIA-C (21.4%) (Fig 1). In competing
risk regression, we observed increasing relative risks of VTE according to this rule (cS IA-B:
reference category; cS IS-IIB: SHR = 3.45, 95%CI: 1.13–10.53, p = 0.03; cS IIC: SHR = 8.86,
95%CI: 2.35–33.45, p = 0.001; cS IIIA-C: SHR = 13.82, 95%CI: 5.88–32.51, p<0.0001). The
rule discriminated well between patients who did and did not develop VTE during the first
12-months of follow-up (Harell’s C Index = 0.77). In comparative ROC analysis, we observed
that a classifier according to these 4 categories had a significantly higher discriminatory perfor-
mance with respect to VTE than the RPLN-VTE-risk-classifier according to Srikanthan et al.
(AUC-ROC: 0.75 vs. 0.63, p for difference = 0.007).
External validation
In the Zurich cohort comprising 349 TGCT patients [Stage IA-B: n = 226 (64.8%), Stage
IS-IIB: n = 50 (14.3%), Stage IIC: n = 9 (2.6%), Stage IIIA-IIIC: n = 64 (18.3%)], we observed
Fig 1. 12-month-cumulative VTE incidence in the Graz cohort.
https://doi.org/10.1371/journal.pone.0176283.g001
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18 VTE (5.2%) events. In a competing risk analysis the cumulative one-year incidence of VTE
according to our proposed risk stratification categories was highly similar to our development
cohort (Fig 2, Table 6). Also, the C-Index for 12-month VTE discrimination was even higher
than in the Graz cohort (Harell’s C = 0.84). These findings are consistent with the concept that
this score validates in a large external cohort, and represents a valid risk stratification model
for VTE in TGCT patients (Table 6).
In a sensitivity analysis, we re-fitted the risk stratification rule in the Graz and Zurich
cohorts with a prediction time horizon of 3 and 6 months instead of 12-months. The risk strat-
ification rule featured a very high discriminatory potential for these horizons as well (C-Index
for 3-month VTE risk in the Graz cohort = 0.79, for 6-month VTE risk in the Graz
Fig 2. 12-month-cumulative VTE incidence in the Zurich cohort.
https://doi.org/10.1371/journal.pone.0176283.g002
Table 6. Externally validated risk stratification model for VTE in TGCT patients.
Risk category 12 month VTE risk (Graz cohort) 12 month VTE risk (Zurich cohort)
Stage IA—IB 2% 1%
Stage IS—IIB 6% 6%
Stage IIC 14% 11%
Stage IIIA—IIIC 21% 19%
https://doi.org/10.1371/journal.pone.0176283.t006
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cohort = 0.81, for 3-month VTE risk in the Zurich cohort = 0.86, and for 6-month VTE risk in
the Zurich cohort = 0.84), which these C-Indices being comparable to the one observed with a
12-month horizon.
In a further analysis, we compared our risk rule with the Srikanthan model in the Zurich
cohort. In concordance with the Graz cohort, the risk rule also here discriminated better
according to future VTE status than the Srikanthan model (ROC-AUC = 0.88 vs. 0.76,
p = 0.04).
Moreover, we compared the herein proposed risk rule with the Srikathan model in the
Graz cohort, but restricted the population to patients that received chemotherapy for metastas-
tic TGCT (i.e. cS IS-IIIC, n = 177, i.e. a population that is comparable to the population on
which the Srikanthan model was developed). Here, the risk stratification had a higher
AUC-ROC for VTE (0.65) than the Srikanthan model (0.61), however, this was not statistically
significant at the 5% level (p = 0.50). However, in this subgroup of patients the Srikanthan
model did not reach significance with respect to discrimination than chance, i. e. the 95% CI
of the AUC-ROC includes 0.5 (AUC-ROC = 0.61, 95% CI 0.498–0.757). Our proposed risk
stratification rule, showed a significant discriminatory capability as well in the Graz cohort
(AUC-ROC = 0.65, 95%CI: 0.56–0.79) as well as in the Zurich cohort (AUC-ROC = 0.68, 95%
CI: 0.51–0.78).
Exploring the clinical risk/benefit-ratio of primary prophylaxis of VTE in
TGCT patients
Assuming a 50% relative reduction of the risk of VTE with primary prophylaxis, the numbers-
needed-to-treat to prevent one VTE event were 118, 34, 14 and 9 in patients with cS IA-B, cS
IS-IIB, cS IIC, cS IIIA-C respectively [25]. Assuming a 25% increase in the relative risk of
major and clinically relevant non-major bleeding with primary prophylaxis of VTE, the num-
bers-needed-to-harm was 125 [25].
Discussion
In our study population of 657 TGCT patients we have observed an unevenly distributed VTE
risk. In stage I TGCT patients the risk of VTE is low, particularly in patients who do not
undergo adjuvant chemotherapy. In contrast, TGCT subgroups with a large RPLN and/or dis-
tant metastases have a very high risk of VTE. This raises the question whether these patients
might benefit from primary prophylaxis.
In unselected patients, the incidence of VTE was 5.2% in the Graz and in the Zurich cohort.
In patients with metastatic disease 24 (13.6%) out of 177 patients in the Graz cohort developed
a VTE. This again correlates with the VTE rate in the validation cohort of 13.0%.
We confirmed that a large RPLN emerged as a strong risk factor validating the results by
Srikanthan et al.[13]. However, in our study population the VTE risk in patients with distant
metastases was even higher than in patients with a large RPLN. This observation was also vali-
dated in the Zurich cohort and may reflect the increased risk of VTE in a more advanced stage
of malignancy with presence of greater burden of disease.
In univariable analysis, we could also confirm that the Khorana score identifies patients
with elevated risk for VTE. However, only 9 patients out of our total 657 fell into the high risk
category with a Khorana Score 3, but none of them developed a VTE event, suggesting that
the Khorana score may be less useful. Therefore performance of the model was compared with
the TGCT-specific model of Srikathan et al. and not the Khorana score. Univariable modeling
results indicated an adverse impact of RPLN on VTE risk. This finding is highly consistent
with the results of Srikanthan et al. We further showed that our proposed risk stratification
Testicular cancer and thromboembolism
PLOS ONE | https://doi.org/10.1371/journal.pone.0176283 April 21, 2017 11 / 15
rule provides a higher discriminatory accuracy in the risk assessment for VTE than the Sri-
kanthan model in the whole population [13]. In patients with metastatic disease, our proposed
rule was numerically but not statistically significantly better with respect to discrimination
than the Srikanthan model. However, in this subgroup of patients the Srikanthan model did
not reach significance with respect to discrimination than chance, given the 95% CI of the
AUC-ROC includes 0.5. This is an interesting finding because the Srikanthan model had also
not reached statistical significance in their validation cohort (AUC-ROC = 0.61, 95%CI: 0.43–
0.80)[13], whereas our model validates in its external validation cohort from Zurich.
In patients with metastasized cS IS-IIIC disease, undergoing curative chemotherapy, higher
tumor stage and a large RPLN were the main risk factors for VTE. Therefore these two predic-
tors built the basis for our risk stratification. We also found some highly significant univariable
associations between the properative tumor markers LDH, betaHCG, AFP and VTE risk.
However, except for LDH, these differences became much weaker / lost their statistical signifi-
cance after adjusting for tumor stage. This means that elevations of the tumor markers likely
reflect higher tumor stages, which are associated with a high VTE risk.
No thromboembolic events occurred between orchiectomy and the start of chemotherapy.
In our observation, the risk of VTE increased immediately after the initiation of chemotherapy
which can be explained by cisplatin-induced vascular toxicity [7,27]. Only a negligible amount
of events occurred after treatment had been completed. Furthermore, the risk of VTE
increased with the number of cycles of chemotherapy, suggesting a dose-dependent risk.
The distribution of TGCT patients according to tumor stage and the incidence of VTE
were highly similar in the Graz cohort and the validation cohort from Zurich. Most of TGCT
patients present with cS I disease. According to our analysis their VTE risk was low and pri-
mary prophylaxis of VTE will have an unfavorable risk-benefit ratio. Conversely, patients with
cS IIC and cS III disease carry a very high risk of VTE according to our risk classification.
Therefore the numbers-needed-to-treat to prevent one VTE event are relatively low (cS IIC: 14
treated patients, C III: 9 treated patients) based upon relative risk reductions of 50% as shown
in prior studies [25]. There is evidence showing that primary prophylaxis works in all (Khor-
ana) risk groups. However, selecting high risk groups may select a population whose risk-bene-
fit ratio with primary prophylaxis will be more favourable. Two reported randomized phase III
trials focused on primary prophylaxis of VTE among unselected cancer outpatients treated
with chemotherapy and demonstrated a significant reduction in the rate of VTE with primary
prophylaxis [25,28]. In the SAVE-ONCO study semuloparin, an ultra-low-molecular-weight
heparin, showed a 64% relative risk reduction when compared with placebo [25]. The approval
of Semuloparin for prophylaxis of VTE in ambulatory cancer patients was rejected in the
United States because of the low event rate of VTE leading to a high number-needed-to-treat
and unfavorable risk-benefit profile in an unselected cancer population. Current guidelines
thus do not recommend routine prophylaxis of VTE in the outpatient setting except for
patients with multiple myeloma receiving thalidomide-lenalidomide-based treatments [29,30].
However, both trials did not include patients with TGCT who have a higher risk. In the Graz
cohort the cumulative incidence of VTE was 21% in cS III and 14% in cS IIC patients. In the
Zurich cohort these figures were similar with corresponding risks of 19% and 11%. This com-
pares with an incidence of VTE between 17% and 26% in myeloma patients treated with tha-
lidomide or lenalidomide without thromboprophylaxis [31]. In summary, this allows us to
speculate that TGCT patients are a cancer population which may have a benefit from primary
thromboprophylaxis.
Strengths of this manuscript include a large sample size and an external validation in a large
cohort from a different country which yielded highly similar results to the development
cohort. Another important strength of our study and the proposed risk model is that this data
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are applicable to the full spectrum of TGCT patients (and not only to the metastatic setting as
investigated by Srikanthan et al.). Further, we could show that the proposed risk stratification
rule provides a better discrimination than the Srikanthan model. Moreover, we found that not
only RPLN as demonstrated by Srikanthan is a strong risk factor for VTE, but that in addition,
stage III disease adds further prognostic information beyond this variable. The Srikanthan
model, which was designed specifically for the TGCT setting, already showed better discrimi-
nation than the Khorana score. Synoptically, this is consistent with the assumption that to
date, our risk stratification rule provides a superior tool for stratifying TGCT patients accord-
ing to their VTE risk.
The major limitation of the present analysis is its retrospective data collection. Some VTE
events may have been missed due to incomplete documentation. This also applies to ascertain-
ment of the primary thromboprophylaxis status. Another limitation is that some VTE events
may have occurred outside of our hospital network, which may have led to an underestimation
of VTE risk. However, given the observation that most VTEs occur during antineoplastic ther-
apy (where patients are routinely seen at our department) and records of nearly all hospitals in
our referral area were accessible by the retrospective data collection team (joint public hospital
trust with common IT system and electronic healthcare database), we consider the probability
of a VTE rate underestimation to be minimal.
Conclusions
We demonstrated that TGCT subgroups with large retroperitoneal disease and/or distant
metastases carry a very high risk for VTE. These subgroups can be identified with an exter-
nally-validated risk assessment model based on the clinical tumor stage, and may benefit from
thromboprophylaxis and other management strategies. The efficacy and safety of this
approach, as well as optimal thresholds to justify primary prophylaxis of VTE, warrant pro-
spective investigation. In the absence of prospective data, this study supports the concept that
that primary prophylaxis of VTE may be worthwhile in patients with cS IIC and cS III TGCT
for the duration of their chemotherapy.
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